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 Background: The complete medical consequences of the long-term exposure of population to ionizing radiation in post-Chernobyl 
period are still a controversial issue. The molecular biological analysis of malignant diseases of hematopoietic and lymphoid tissues 
in contaminated territories requires the precise diagnosis based on criteria of novel classifications. Aim: To analyze the relative gene 
expression of six apoptosis-related genes in different types of tumors of hematopoietic and lymphoid tissues in patients living in areas 
of Ukraine contaminated with radionuclides in post-Chernobyl period. Material and methods: The samples of the peripheral blood and 
bone marrow of 189 Ukrainian leukemia patients and 16 patients with reactive lymphocytosis were analyzed morphologically and im-
munocytochemically for precise delineation of the main forms and cytological variants of hematological malignancies according to new 
WHO classification. Expression of six apoptosis-related genes was analyzed in the individual samples of 9 different groups of malignant 
diseases of hematopoietic and lymphoid tissues and one group of patients with reactive lymphocytosis by quantitative RT-PCR. Ex-
pression of genes was assessed relative to that in control group of healthy donors. Results: Up-regulation of six analyzed apoptosis-
related genes is observed in all groups of leukemia. In most groups of leukemia being analyzed, BCL-2 up-regulation level is superior 
to that of BAX. Prominent MYC up-regulation is observed in B-lymphoblastic leukemia/lymphoma, non-Hodgkin’s lymphoma, and 
T-lymphoblastic leukemia/lymphoma groups. In myelodysplastic/myeloproliferative neoplasms, the striking up-regulation of Fas-1 and 
P38MAPK is evident. Practically all the groups of leukemia are characterized by stable high ratios of P53 up-regulation. Conclusion: 
In Ukrainian patients, up-regulation of six analyzed apoptosis-related genes is observed practically in all types of malignant diseases 
of hematopoietic and lymphoid tissues under study. Microarray-based analysis of these samples would be of great importance in terms 
of elucidating genomic interactions in leukemias and their possible association with ionizing radiation.
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Chernobyl nuclear accident on April 26, 1986, led 
to a massive release of radionuclides into the environ-
ment. Although the vast areas of Europe were affected 
by Chernobyl-related ionizing radiation, the most 
contaminated territories are located in Ukraine, Re-
public of Belarus, and Russian Federation. In Ukraine, 
in particular, 2293 towns and villages in 74 administra-
tive units of 12 administrative regions are considered 
as contaminated with radionuclides. As of the begin-
ning of 2011, more than 2.15 million people inhabit the 
contaminated territories being subjected for a long 
time to the continuous exposure to low doses of ion-
izing radiation IR. 
Up to present, the data on the possible medical 
consequences of irradiation due to Chernobyl accident 
are inconsistent. Nevertheless, IR is an ever-present 
hazard to humans primarily due to its mutagenic, 
carcinogenic, and cell killing ability [1]. Chromosome 
aberrations and gene mutations induced by IR are 
conventionally attributed to DNA being irreversibly 
changed immediately after exposure, either during 
the processing and enzymatic repair of the damage 
or during DNA replication. As malignant transforma-
tion is generally regarded as being initiated by a gene 
mutation or a chromosomal aberration, the initiating 
lesion for malignant transformation has been simi-
larly attributed to DNA damage in a directly irradiated 
target cell [2]. IR is implicated in the development 
of some forms of acute and chronic leukemia (except 
for chronic lymphocytic leukemia — CLL, that until 
recently has not been thought to be associated with 
radiation exposure), multiple myeloma, primary my-
elofibrosis, erythremia, non-Hodgkin’s lymphoma, 
myelodysplastic syndromes (MDS) [3] with the largest 
risk for acute myeloid leukemia (AML) [4]. 
Apoptosis plays a key role in the control of rapidly 
renewing tissues, such as the hematopoietic system. 
Leukemic cells invariably have abnormalities in one 
or more apoptotic pathways providing a survival ad-
vantage of these cells and the development of drug 
resistance. The susceptibility of normal and cancer 
cells to induction of apoptosis depends on the balance 
between proapoptotic and antiapoptotic genes. The 
analysis of mutations and gene expression of apop-
tosis-related proteins such as Bcl-2, Bax, Myc, Fas-1, 
p38 MAPK and p53 may be of importance in predicting 
the patient response to chemo- or radiotherapy as well 
as patient’s survival. The different expression levels 
and post-translational modifications of these proteins 
may determine cell sensitivity to apoptosis.
The aim of the study was to analyze the relative 
gene expression of six apoptosis-related genes 
in different types of tumors of hematopoietic and lym-
phoid tissues in 189 patients living in areas of Ukraine 
contaminated with radionuclides in post-Chernobyl 
period. These results may be important to search for 
possible markers specific of the leukemogenic ef-
fects of IR.
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MATERIALS AND METHODS
The samples of the peripheral blood of 189 leukemia 
patients and 16 patients with reactive lymphocytosis 
upon fractionation in Ficoll-Verografin were obtained 
from R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology of the National Academy 
of Sciences of Ukraine. All the patients were referred 
to the Reference Laboratory of Immunocytochemistry 
and Oncohematology Department of the Institute for 
verifying the diagnosis. Control group comprised the 
peripheral blood samples of 30 healthy donors from Kyiv 
city. The design of the study was approved by the ethic 
committees of both collaborating research institutions. 
Bone marrow and peripheral blood smears stained 
by May-Grunwald-Giemsa were studied morpho-
logically. Immunocytochemical techniques (APAAP, 
LSAB-AP) and a broad panel of monoclonal antibodies 
(MoAbs) against lineage specific, differentiation and 
activation antigens of leukocytes were employed for 
immunophenotyping pathological cells in blood and 
bone marrow. The main forms and cytological vari-
ants of hematological malignancies were diagnosed 
according to new WHO classification [5].
Total RNA was isolated from mononuclear cells 
of each patient using QIAamp RNA Blood Mini Kit 
(QIAGEN, Valencia, CA, USA) and treated with DNase 
I according to the manufacturer’s instructions. cDNA 
was synthesized using RevertAid First Strand cDNA 
Synthesis Kit (Fermentas Inc., Maryland, USA). Quan-
titative RT-PCR was performed at the Medical Genetics 
Department, Medicine Faculty of Kocaeli University, 
Turkey as we described previously [6, 7]. Standard 
curves were obtained using serial dilutions of the beta-
globulin gene (DNA Control Kit, Roche). Gene-specific 
primers (Table 1) were obtained from Integrated DNA 
Technologies (Iowa, USA). Obtained gene expression 
values were normalized using a housekeeping gene 
of beta2 microglobulin. Gene expression ratios were 
compared in patient and control groups using REST 
(Relative Expression Software Tool).
RESULTS AND DISCUSSION
Expression of six genes (BCL-2, BAX, MYC, FAS-1, 
P38MAPK, P53) was studied in samples of 189 leukemia 
patients. These samples were divided into 9 different 
groups of malignant diseases of hematopoietic and 
lymphoid tissues. One further group comprises 16 pa-
tients with reactive lymphocytosis. Table 2 summarizes 
the specific gene expression levels of these groups. 
In general, up-regulation of six analyzed genes 
is observed in all groups of leukemia. Low levels 
of down-regulation of FAS-1 in B-cell prolympho-
cytic leukemia and MYC in T-cell leukemia from large 
granular lymphocytes are observed on small number 
of patients. Stable and high ratios of up-regulation 
of P53 in all groups are conspicuous. 
The high ratio of Bcl-2 to Bax proteins has been 
shown to confer an unfavorable prognosis with de-
creased rates of complete remission and overall sur-
vival. BCL-2 down-regulation might lower the apoptotic 
threshold of leukemic cells and, through this mecha-
nism, favors response to chemotherapy [8]. According 
to the previous studies, correlation between apoptosis 
and up-regulation of BAX gene was observed in pe-
diatric acute lymphoblastic leukemia (ALL) samples 
[9]. In our study, BCL-2 up-regulation level is superior 
to that of BAX for all groups being analyzed. 
In our findings, MYC gene up-regulation is ob-
served, in particular, in B-lymphoblastic leukemia/
lymphoma, non-Hodgkin’s lymphoma, and lymphocy-
tosis groups. The highest values of MYC up-regulation 
are observable in T-cell lymphoblastic leukemia-
lymphoma. Many forms of leukemia are associated 
with specific genetic events, often resulting in MYC 
proto-oncogene activation. Myc is very often found 
to be up-regulated in many types of cancers. The mi-
croarray study demonstrated up-regulation of c-MYC 
gene in B-CLL samples [10]. All these results are con-
sistent with our findings and confirm that MYC gene 
has an important role in regulation of cell cycle.
In our study, a tendency to rising FAS expression 
in B-cell leukemia, lymphoma, and in the patients 
with reactive lymphocytosis is compatible with our 
expectations. A high rise of FAS expression in MDS 
group is remarkable. Cells from several hematologi-
cal tumors are known to express Fas on their surface. 
Usually, in B-CLL Fas expression is not very high [11] 
Table 2. Gene expression levels (relative to those in healthy controls) in cells of different types of tumors of hematopoietic and lymphoid tissues: U — up-
regulation, D — down-regulation
Number of pts BCL-2 BAX MYC FAS-1 P38MAPK P53
B-CLL/B-cell lymphoma from small lymphocytes 127 16.696 U 5.0265 U 4.15 U 4.536 U 3.263 U 20.3415 U
B-cell prolymphocytic leukemia 4 9.221 U 1.717 U 9.931 U 1.550 D 1.436 D 2567.236 U
B-cell non-Hodgkin’s lymphoma 26 22.722 U 10.056 U 18.870 U 248.310 U 82.025 U 264.111 U
B-lymphoblastic leukemia/lymphoma 7 16.819 U 14.113 U 18.804 U 161.233 U 5.333 U 29.000 U
T-cell leukemia from large granular lymphocytes 4 1.936 U 1.221 U 1.324 D 1.871 U 1.166 U 3.401 U
T-lymphoblastic leukemia/lymphoma 6 227.229 U 45.443 U 210.256 U 15.043 U 2898.318 U 30828.990 U
Myelodysplastic / Myeloproliferative neoplasms 5 77.172 U 11.104 U 24.369 U 5326.603 U 1257.201 U 30.400 U
Chronic myelogenous leukemia 6 17.692 U 14.470 U 12.185 U 8.610 U 8.225 U 23.736 U
Hairy cell leukemia 4 29.243 U 12.711 U 10.883 U 9.113 U 12.623 U 69.358 U
Patients with reactive lymphocytosis 16 29.182 U 8.622 U 19.794 U 374.806 U 9.918 U 172.088 U
Table 1. Primer sequences of the studied genes
Genes Primer sequences
Beta2 microglobulin (F) 5’ TGA CTT TGT CAC AGC CCA AGA TA 3’
(R) 5’ AAT CCA AAT GCG GCA TCT TC 3’
BCL-2 (F) 5’ AGG AAG TGA ACA TTT CGG TGA C 3’
(R) 5’ GCT CAG TTC CAG GAC CAG GC 3’
BAX (F) 5’ TGC TTC AGG GTT TCA TCC AG 3’
(R) 5’ GGC GGC AAT CAT CCT CTG 3’
MYC (F) 5’ GGC AAA AGG TCA GAG TCT GG 3’
(R) 5’ GTG CAT TTT CGG TTG TTG C 3’
FAS-1 (F) 5’ CAA GGG ATT GGA ATT GAG CA 3’
(R) 5’ GAC AAA GCC ACC CCA AGT TA 3’
P38MAPK (F) 5’ GCC CAA GCC CTT GCA CAT 3’
(R) 5’ TGG TGG CAC AAA GCT GAT GAC 3’
P53 (F) 5’ CTG GCC CCT GTC ATC TTC TG 3’
(R) 5’ CCG TCA TGT GCT GTG ACT GC 3’
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that coincides with our findings of relatively small up-
regulation. It is of interest to note that even the low 
doses of radiation were sufficient to modulate Fas 
expression [12]. Although the relationship between 
Fas/FasL system and apoptosis were shown in pe-
ripheral T cells, FasL expression is practically absent 
in T-cell lymphoblastic lymphomas [13]. In our study 
the moderate level of up-regulation in T-lymphoblastic 
leukemia/lymphoma group was shown. In another 
study, in AML samples in Chernobyl clean-up workers, 
Fas receptor was expressed more rarely than in AML 
that was not associated with radiation exposure [14]. 
An increased Fas and FasL levels depending on the ef-
fect of irradiation was identified in B-CLL samples [15]. 
Up-regulation of P53 is observed as a stable and high 
marker in almost all studied groups. In another study, 
an increase of radiation-induced P53 level was shown 
in several lymphoblastic cell lines [16]. Characteristic 
P53 damage caused by IR was described in Chernobyl 
patient with Sezary syndrome [17]. P53 gene defects 
stand out especially in B-CLL in multi-gene screening 
[18]. According to our study, all leukemia types ex-
hibited a regular increase in expression of P53 gene, 
an important protector of cells. These increased levels 
of gene expression should be examined in terms of di-
agnostic and prognostic values.
Furthermore, in our study a dramatic increase 
of P38Mapk levels is observed in B and T-cell lympho-
ma groups. Analysis of this gene pathway as a target 
area of follicular lymphoma treatment in a microarray 
study has been considered [19].
To summarize, up-regulation of six analyzed genes 
has been observed in all types of malignant diseases 
of hematopoietic and lymphoid tissues under study. 
The stable and high ratios of P53 up-regulation in all 
groups are noticeable. Microarray-based analysis 
of these samples would be of great importance 
in terms of IR and genomic interactions in leukemias.
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